From: A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer’s disease
Study | Sample | Database | Neuropathological criteria | Autopsy | Dementia criteria |
---|---|---|---|---|---|
McKeith et al ., 1992 [[20]] | AD 37 | Newcastle, UK | AD: plaque/tangle quantification, H + E, CFV, Loyez, Palmgren. | All | DLB: proposed consensus (1992) |
SDLT 21 | |||||
LB: H + E, pholxine, erythrosin | |||||
Ballard et al ., 1996 [[17]] | AD 53 | West Midlands and Bristol, UK | 0 | AD: NINCDS/ADRDA (1984) | |
SDLT 7 | DLB: McKeith, operational criteria for senile dementia of Lewy body type (1992) | ||||
VaD 14 | |||||
Ballard et al., 1998 [[21]] | AD 30 | Newcastle General Hospital, UK | AD: CERAD, plaque - Braunmuhl stain, tangle - modified Palmgren | 19 | AD: NINCDS/ADRDA (1984) |
DLB 42 | DLB: McKeith, operational criteria for senile dementia of Lewy body type (1992) | ||||
LB: consensus criteria (1996), ubiquitin, anti-tau2, anti-Alz50, anti-AT8 to detect and distinguish cortical LB | |||||
Olichney et a l., 1998 [[3]] | AD 148 | Cohort from: | AD: CERAD, ADRC | All | AD: NINCDS/ADRDA (1984), |
LBV 40 | Univeristy of California, San Diego Alzheimer’s Disease Research Center, USA; | LB: ubiquitin, H + E (brainstem, cerebral cortex) | DSM-III for dementia | ||
CERAD centers, multinational | |||||
Heyman et al ., 1999 [[18]] | AD 74 | Subjects with premortem diagnosis of probable and possible AD from 24 centers participating in CERAD, 1986 to 1995, USA | AD: CERAD | All | AD: NINCDS/ADRDA (1984) |
AD/LBV 27 | LB: consensus criteria (1996), modified (brainstem, limbic/transitional and noecortical). | ||||
Lopez et al ., 2000 [[22]] | AD 98 | University of Pittsburg 1983 to 1998, USA | AD: CERAD, NIA-RI | All | AD: NINCDS/ADRDA (1984) |
AD/DLB 44 | LB: H + E, ubiqutin (SN, neocortex, limbic areas) | DLB: consensus criteria (1996) | |||
Stern et al . 2001 [[23]] | AD 32 | From cohort of 236 patients with probable AD | AD: CERAD | All | AD: NINCDS/ADRDA (1984) |
LBV 19 | LB: semi quantitative ubiquitin (SN, hippocampus, cingulate gyrus, insula cortex) | ||||
Recruited: | |||||
Columbia University College, New York, USA | |||||
Johns Hopkins University, Baltimore, USA | |||||
Massachusetts General Hospital, Boston, USA | |||||
Ballard et al ., 2001 [[24]] | AD 101 | Cohort of 227 patients | AD: CERAD, plaque - Braunmuhl stain, tangle - modified Palmgren | 50 | AD: NINCDS/ADRDA (1984) |
DLB 64 | Institute of the Health of the Elderly (IHE), Newcastle, UK | DLB: consensus criteria (1996) | |||
VaD 38 | LB: consensus criteria (1996), ubiquitin, anti-tau2, anti-Alz50, anti-AT8 to detect and distinguish cortical LB | ||||
Helmes et al ., 2003 [[25]] | AD 15 | University of Western Ontario Dementia Study, Canada | No criteria are referred to. Only referred to LB staining methods (Bielschovsky, anti-ubiquitin, anti-synuclein). | All | Not specified. |
AD/DLB 8 | |||||
DLB 7 | |||||
Johnson et al ., 2005 [[26]] | AD 66 | Washington University, from 1979, USA | AD: NIA-RI quantification of diffuse and neuritic depositions in 10 cortical regions | All | AD: NINCDS/ADRDA (1984) |
AD/DLB 57 | DLB: consensus criteria (1996) or McKeith, operational criteria for senile dementia of Lewy body type (1992) | ||||
DLB 9 | LB: synuclein | ||||
Kraybill et al ., 2005 [[15]] | AD 48 | Cohort from University of Washington/Group Health Cooperative Alzheimer’s Disease Patient Registry, USA | AD: CERAD, Braak stages > IV | All | AD: NINCDS/ADRDA (1984) |
AD/LBP 65 | LB/AD: AD + synuclein (amygdala, SN) | DLB: missing criteria because study was started before the consensus criteria for DLB was established. | |||
LBP 22 | |||||
LB: Braak stages < III, synuclein (amygdala, SN) | |||||
Stavitsky et a l., 2006 [[19]] | AD 55 | Cohort of the Predictors Study, 1997: | AD: CERAD | 12 | AD: NINCDS/ADRDA (1984) |
DLB 28 | LB: semi quantitative ubiquitin (hippocampus, cingulate gyrus, insula cortex) | DLB: consensus criteria (1996) | |||
Columbia University | |||||
Johns Hopkins University, | |||||
Massachusetts General Hospital, USA | |||||
Williams et al ., 2006 [[27]] | AD 252 | Cohort from Washington University, USA | AD: NIA-RI quantification of diffuse and neuritic depositions in 10 cortical regions | All | AD: NINCDS/ADRDA (1984) |
DLB 63 | DLB: consensus criteria (1996) | ||||
LB: synuclein | |||||
Hamilton et al ., 2008 [[28]] | AD 44 | University of California, Alzheimer’s disease center San Diego, 1985 to 2002, USA | AD: modified Braak staging, NIA-RI (1997) and CERAD (1991) | All | AD: NIA-RI and CERAD (1988) |
DLB 22 | DLB: consensus criteria (1996) | ||||
LB: H + E, ubiquitin (1996) synuclein (2005) | |||||
Hanyu et al ., 2009 [[29]] | AD 111 | Memory Clinic of Tokyo Medical University, 2000 to 2006, Japan | 0 | AD: NINCDS/ADRDA (1984) | |
DLB 56 | DLB: consensus criteria (1996) | ||||
Nelson et al ., 2009 [[16]] | AD 107 | National Alzheimer’s Coordinating Center (NACC) Registry - 31 AD centers in USA, | AD: NIA-RI | All | AD: CERAD (1988) |
AD/DLB 27 | University of Kentucky Alzheimer’s Disease Center, USA | LB: Braak staging and CERAD | DLB: consensus criteria (1996) | ||
DLB 9 | |||||
Wood et a l., 2012 [[30]] | AD 16 | Newcastle University, UK | 0 | AD: NINCDS/ADRDA (1984) | |
DLB 12 | DLB: consensus criteria (2005) or (1996) | ||||
Walker et al . 2012 [[31]] | AD 100 | 40 European sites | 123I-FTP-SPECT as verifying method | 0 | AD: NINCDS/ADRDA (1984) |
DLB 58 | DLB: consensus criteria (1996) |